Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

JAK2 V617F mutation and the clinical features in myeloproliferative disorders (CROSBI ID 528894)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Radić Antolic, Margareta ; Boban, Ana ; Zadro, Renata ; Juričević, Mirjana ; Sučić, Mirna ; Bašić-Kinda, Sandra ; Labar, Boris JAK2 V617F mutation and the clinical features in myeloproliferative disorders // Leukemia research / Bennet, J.M. ; Hamblin, T.J. (ur.). 2007. str. S80-S80

Podaci o odgovornosti

Radić Antolic, Margareta ; Boban, Ana ; Zadro, Renata ; Juričević, Mirjana ; Sučić, Mirna ; Bašić-Kinda, Sandra ; Labar, Boris

engleski

JAK2 V617F mutation and the clinical features in myeloproliferative disorders

Myeloproliferative disorders share clinical and biological similarities that may be influenced by presence of recently discovered point mutation in JAK2 gene (JAK2 V617F). The aim of this study was to determine the correlation between JAK2 V617F mutation and the clinical features of patients with polycythemia vera (PV) and essential thrombocythemia (ET). The study included 36 patients with PV (PV group) and 38 patients with ET (ET group). The diagnosis was established according to the Polycythemia Vera Study Group criteria. The detection of JAK2 V617F was performed by allele specific PCR (Baxter et al., Lancet 2005) on DNA isolated from bone marrow cells or peripheral blood cells. JAK2 V617F positive and negative members of PV and ET groups were analyzed for peripheral blood counts and bone marrow aspiration. JAK2 V617F positive PV patients exhibited statistically significantly higher number of red blood cells, white blood cells and platelets when compared to PV patients negative for JAK2 V617F. No statistically significant difference was found in hemoglobin concentration and hematocrit value. In contrast, JAK2 V617F positive subjects of the ET group had statistically significantly increased number of red blood cells, hemoglobin concentration and hematocrit value, and no significant difference in platelet or white blood cell count. Bone marrow evaluation revealed that JAK2 V617F positive patients of the PV group had myeloid hyperplasia with the excess of eosinophils and platelet clumps, which is consistent with the findings of the peripheral blood analysis. On the contrary, bone marrow evaluation of the ET group did not reveal any significant differences between JAK2 V617F positive and negative patients. Overall our data suggest that JAK2 V617F mutation status could serve as a criterion to categorize both PV and ET patients into distinct subgroups. Further studies are needed to determine whether JAK2 V617F mutation status in myeloproliferative disorders should be used as a criterion for therapy approach.

JAK2 V617F; myeloproliferative disorders

doi: 10.1016/S0145-2126(07)70383-1

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

S80-S80.

2007.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Leukemia research

Bennet, J.M. ; Hamblin, T.J.

Elsevier

0145-2126

Podaci o skupu

Leukemia and Lymphoma 2007 : West and East Together

poster

15.09.2007-19.09.2007

Dubrovnik, Hrvatska

Povezanost rada

Temeljne medicinske znanosti

Indeksiranost